EchoLaser is now NMPA approved
Elesta announces that the Chinese regulatory authority National Medical Products Administration (NMPA) has approved EchoLaser for use in prostatic diseases. This approval is a major achievement and represents a great opportunity for Elesta (distributed in China by Esaote). NMPA approval confirms once again the robustness of clinical data in urology, where EchoLaser has been demonstrated to be a safe and efficacious alternative to surgery for the treatment of Benign Prostatic Hyperplasia (BPH) and some forms of prostatic cancer.
New office dedicated to the EchoLaser in Cisanello, Pisa
Exciting News in Medical Innovation! EchoLaser for Thyroid
The advantages of EchoLaser for the thermoablation of thyroid nodules are clear and obvious.
This explains DR. Fedele Antonio De Marino, Expert in the field.
Contact us to learn more : info@elesta-echolaser.com
https://napoli.repubblica.it/dossier-adv/eccellenze-della-campania/2024/05/21/news/noduli_alla_tiroide_ecco_come_affrontarli-423114593/
EchoLaser on Corriere della Sera
Elesta EchoLaser has been featured on Corriere della Sera, number one newspaper in Italy by circulation and readership.
Its urology application for the treatment of BPH symptoms is TPLA (transperineal laser ablation), aka SoracteLite.
It is a novel technique which is gaining fast adoption internationally. Safety and efficacy profile was confirmed by many publications, which include two RCT’s vs TURP and one systematic review. Despite new, durability data on this treatment modality at 2 and 3 years are also published (5 years data coming soon).
Link to the article: https://www.corriere.it/salute/sportello_cancro/24_aprile_01/ipertrofia-della-prostata-quando-operare-e-quali-sono-le-tecniche-piu-indicate-a-seconda-anche-dell-eta-29c017e9-d1a3-49a7-abf7-cfe11e525xlk.shtml